MHR与慢性肾脏病心血管并发症的相关研究进展
Research Progress on MHR and Cardiovascular Complications of Chronic Kidney Disease
摘要: 近年来，慢性肾脏病的患病人数逐渐升高，心血管疾病是慢性肾脏病最常见并发症及首要死亡原因，给人类健康带来了很大威胁。除了高血脂、糖尿病等传统危险因素外，贫血、钙磷代谢失调、炎症等对心血管意外的发生也有一定的影响。单核细胞数与高密度脂蛋白胆固醇比值(MHR)是反映炎症和氧化应激的一项新指标。本文将对MHR对慢性肾病心血管并发症的相关研究进行综述。
Abstract: In recent years, the number of people with chronic kidney disease (CKD) has gradually increased, and cardiovascular disease is the most common complication and leading cause of death from CKD, which poses a great threat to human health. In addition to traditional risk factors such as hyperlipidemia, diabetes, etc., anemia, calcium and phosphorus metabolism disorders, and inflammation also have a certain impact on the occurrence of cardiovascular accidents. The ratio of monocyte count to HDL cholesterol (MHR) is a novel indicator of response to inflammation and oxidative stress. This article will review the relevant studies on the effects of MHR on cardiovascular complications of chronic kidney disease.
文章引用：康雨. MHR与慢性肾脏病心血管并发症的相关研究进展[J]. 临床医学进展, 2024, 14(8): 1322-1327. https://doi.org/10.12677/acm.2024.1482357

参考文献

[1] Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V., Woodward, M., et al. (2022) Prevalence of Chronic Kidney Disease in Asia: A Systematic Review and Analysis. BMJ Global Health, 7, e007525. [Google Scholar] [CrossRef] [PubMed]
[2] Centers for Disease Control and Prevention (CDC) (2004) State Specific Trends in Chronic Kidney Failure United States 1990-2001. Morbidity and Mortality Weekly Report, 53, 918-920.
[3] Drey, N., Roderick, P., Mullee, M. and Rogerson, M. (2003) A Population-Based Study of the Incidence and Outcomes of Diagnosed Chronic Kidney Disease. American Journal of Kidney Diseases, 42, 677-684. [Google Scholar] [CrossRef] [PubMed]
[4] 呼延逸然, 鲍苗, 鲁滟新, 李振江, 朱燕亭. SphK1和微炎症状态在慢性肾脏病中的作用[J]. 临床医学进展, 2023, 13(5): 8174-8180.
[5] Ganjali, S., Gotto, A.M., Ruscica, M., Atkin, S.L., Butler, A.E., Banach, M., et al. (2018) Monocyte‐to‐HDL‐Cholesterol Ratio as a Prognostic Marker in Cardiovascular Diseases. Journal of Cellular Physiology, 233, 9237-9246. [Google Scholar] [CrossRef] [PubMed]
[6] Kanbay, M., Solak, Y., Unal, H.U., Kurt, Y.G., Gok, M., Cetinkaya, H., et al. (2014) Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Events in Patients with Chronic Kidney Disease. International Urology and Nephrology, 46, 1619-1625. [Google Scholar] [CrossRef] [PubMed]
[7] Cetin, M.S., Ozcan Cetin, E.H., Kalender, E., Aydin, S., Topaloglu, S., Kisacik, H.L., et al. (2016) Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. Heart, Lung and Circulation, 25, 1077-1086. [Google Scholar] [CrossRef] [PubMed]
[8] Canpolat, U., Aytemir, K., Yorgun, H., Şahiner, L., Kaya, E.B., Çay, S., et al. (2015) The Role of Preprocedural Monocyte-to-High-Density Lipoprotein Ratio in Prediction of Atrial Fibrillation Recurrence after Cryoballoon-Based Catheter Ablation. EP Europace, 17, 1807-1815. [Google Scholar] [CrossRef] [PubMed]
[9] Cetin, M.S., Ozcan Cetin, E.H., Kalender, E., Aydin, S., Topaloglu, S., Kisacik, H.L., et al. (2016) Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. Heart, Lung and Circulation, 25, 1077-1086. [Google Scholar] [CrossRef] [PubMed]
[10] Karataş, M.B., Çanga, Y., Özcan, K.S., et al. (2015) Monocyte to High-Density Lipoprotein Ratio as a New Prognostic Marker in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of Emergency Medicine, 34, 240-244.
[11] Açıkgöz, S.A., Açıkgöz, E., Şensoy, B., et al. (2016) Monocyte to High-Density Lipoprotein Cholesterol Ratio Is Predictive of In-Hospital and Five-Year Mortality in ST-Segment Elevation Myocardial Infarction. Cardiology Journal, 23, 505-512.
[12] Çiçek, G., Kundi, H., Bozbay, M., Yayla, C. and Uyarel, H. (2016) The Relationship between Admission Monocyte HDL-C Ratio with Short-Term and Long-Term Mortality among STEMI Patients Treated with Successful Primary PCI. Coronary Artery Disease, 27, 176-184. [Google Scholar] [CrossRef] [PubMed]
[13] Villanueva, D.L.E., Tiongson, M.D., Ramos, J.D. and Llanes, E.J. (2020) Monocyte to High-Density Lipoprotein Ratio (MHR) as a Predictor of Mortality and Major Adverse Cardiovascular Events (MACE) among ST Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis. Lipids in Health and Disease, 19, Article No. 55. [Google Scholar] [CrossRef] [PubMed]
[14] House, A.A., Wanner, C., Sarnak, M.J., Piña, I.L., McIntyre, C.W., Komenda, P., et al. (2019) Heart Failure in Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95, 1304-1317. [Google Scholar] [CrossRef] [PubMed]
[15] Damman, K., Valente, M.A.E., Voors, A.A., O’Connor, C.M., van Veldhuisen, D.J. and Hillege, H.L. (2013) Renal Impairment, Worsening Renal Function, and Outcome in Patients with Heart Failure: An Updated Meta-Analysis. European Heart Journal, 35, 455-469. [Google Scholar] [CrossRef] [PubMed]
[16] Kottgen, A., Russell, S.D., Loehr, L.R., Crainiceanu, C.M., Rosamond, W.D., Chang, P.P., et al. (2007) Reduced Kidney Function as a Risk Factor for Incident Heart Failure. Journal of the American Society of Nephrology, 18, 1307-1315. [Google Scholar] [CrossRef] [PubMed]
[17] Packer, M., Anker, S.D., Butler, J., Filippatos, G., Pocock, S.J., Carson, P., et al. (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383, 1413-1424. [Google Scholar] [CrossRef] [PubMed]
[18] 张楠. 单核细胞/高密度脂蛋白比值与血液透析患者心血管事件的相关性研究[D]: [硕士学位论文]. 重庆: 中国人民解放军海军军医大学, 2021.
[19] 赵伊合帕莱姆∙依拉木. 单核细胞计数/高密度脂蛋白胆固醇比值(MHR)与心力衰竭的相关性研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2023.
[20] 李娜, 张羽, 齐晓瑜, 等. 重症心力衰竭患者血清可溶性生长刺激表达基因2蛋白水平及意义[J]. 中华实用诊断与治疗杂志, 2022, 36(3): 259-262.
[21] 张静. MHR、CHR与慢性肾脏病合并左心室肥厚的相关性研究[D]: [硕士学位论文]. 开封: 河南大学, 2023.
[22] 吴美豪. 单核细胞/高密度脂蛋白比值与慢性肾脏病左心室肥厚及肾功能进展的相关性研究[D]: [硕士学位论文]. 郑州: 郑州大学, 2021.
[23] 宋鑫. MLR、MHR、FAR与MHD患者营养不良和左心室肥厚的相关性研究[D]: [硕士学位论文]. 烟台: 滨州医学院, 2021.
[24] Eyyupkoca, F., Yildirim, O., Sivri, S., Ali-Felekoglu, M., Demirtas, B., Sait-Altintas, M., et al. (2022) Admission Monocyte/HDL Ratio Predicts Adverse Cardiac Remodeling after ST-Elevation Myocardial Infarction. Revista de Investigación Clínica, 74, 104-112. [Google Scholar] [CrossRef] [PubMed]
[25] Suzuki, A., Fukuzawa, K., Yamashita, T., Yoshida, A., Sasaki, N., Emoto, T., et al. (2016) Circulating Intermediate CD14++CD16+monocytes Are Increased in Patients with Atrial Fibrillation and Reflect the Functional Remodelling of the Left Atrium. EP Europace, 19, 40-47. [Google Scholar] [CrossRef] [PubMed]
[26] Banerjee, D., Rosano, G. and Herzog, C.A. (2021) Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology, 16, 1131-1139. [Google Scholar] [CrossRef] [PubMed]
[27] Xiao, L. and Harrison, D.G. (2020) Inflammation in Hypertension. Canadian Journal of Cardiology, 36, 635-647. [Google Scholar] [CrossRef] [PubMed]
[28] Gembillo, G., Siligato, R., Cernaro, V., Satta, E., Conti, G., Salvo, A., et al. (2021) Monocyte to HDL Ratio: A Novel Marker of Resistant Hypertension in CKD Patients. International Urology and Nephrology, 54, 395-403. [Google Scholar] [CrossRef] [PubMed]
[29] Zhou, Y., Dan, H., Bai, L., Jia, L., Lu, B., Gu, G., et al. (2022) Continuous Positive Linear Association between the Monocyte to High-Density Lipoprotein Cholesterol Ratio and Hypertension: A Cross-Sectional Study. International Journal of Hypertension, 2022, Article ID: 8501726. [Google Scholar] [CrossRef] [PubMed]
[30] Aydin, E., Ates, I., Fettah Arikan, M., Yilmaz, N. and Dede, F. (2017) The Ratio of Monocyte Frequency to HDL Cholesterol Level as a Predictor of Asymptomatic Organ Damage in Patients with Primary Hypertension. Hypertension Research, 40, 758-764. [Google Scholar] [CrossRef] [PubMed]

为你推荐